The focus of my research initiatives was in enhancing our understanding of the role of various therapies in treating men and women with voiding dysfunction.  More specifically, the role of various medical and minimally invasive therapies for benign prostatic hyperplasia (BPH) was at the core my NIH and clinical grants.  Through these endeavors, the landscape of BPH therapy has changed dramatically over the past 15 years.  Moreover, the role of early intervention, progression of disease and predictive outcomes have served as templates for current thought. The value of combination therapy for many men based on prostate size and symptom profile is now the standard throughout the world. 

In addition, in my role as fellowship director for the past 20 years, I have helped foster an environment of discovery with many of my fellows working in collaboration and creating scientific impact.  More recently, my research has focused on clinical outcomes and economic modeling in various aspects of urologic care and more specifically, Men’s Health.  The role of diabetes, cardiovascular disease and aging on pelvic health emanated from work done with other groups such as the Boston Area Community Health Survey.

At Mount Sinai, my goal is to help build a clinical research infrastructure that will use digital informatics with enhanced uploading of epidemiologic and clinical data among the various entry points in the Men’s Health Network to be created throughout Manhattan.  Longitudinal and dynamic monitoring will allow for the development of predictive treatment algorithms and enhance quality of care and outcomes.